<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="15085">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02072408</url>
  </required_header>
  <id_info>
    <org_study_id>2013-10-044-002</org_study_id>
    <nct_id>NCT02072408</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Intravitreal Vascular Endothelial Growth Factor Trap-eye in Patients With Polyploidal Choroidal Vasculopathy</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Samsung Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Seoul National University Bundang Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kim's Eye Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Samsung Medical Center</source>
  <oversight_info>
    <authority>Korea: Institutional Review Board</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate  the efficacy and safety of aflibercept for
      treatment of polypoidal choroidal vasculopathy without active polyp.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2014</start_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Change of best-corrected visual acuity (ETDRS letters)</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>presence of subretinal hemorrhage</measure>
    <time_frame>during 1 year</time_frame>
    <safety_issue>No</safety_issue>
    <description>Total number of months when subretinal hemorrhage are detected on fundus photographs.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of fluid in macula evidenced by optical coherence tomography</measure>
    <time_frame>during 1 year</time_frame>
    <safety_issue>No</safety_issue>
    <description>Total number of months when fluid in macula are detected on optical coherence tomography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change of indocyanine green angiography</measure>
    <time_frame>during 1 year</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change of indocyanine green angiography will include followings
New appearance of polypoidal structure
Any change in size of the greatest linear dimension of lesion
Any change in size and activity of branching vascular network</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of eyes which need rescue treatment (photodynamic therapy)</measure>
    <time_frame>during 1 year</time_frame>
    <safety_issue>No</safety_issue>
    <description>In this study, photodynamic therapy will be performed as a rescue therapy according to the necessary criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>safety outcomes</measure>
    <time_frame>one year</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>frequency and severity of ocular adverse event</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">46</enrollment>
  <condition>Polypoidal Choroidal Vasculopathy Without Active Polyp</condition>
  <arm_group>
    <arm_group_label>polypoidal choroidal vasculopathy without polyp</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>aflibercept</intervention_name>
    <description>Three monthly intravitreal aflibercept (2mg) injections
Five bimonthly intravitreal aflibercept (2mg) injections
Rescue treatment: Verteporfin photodynamic therapy
Loss of five ETDRS letters or one Snellen line of vision from baseline
Presence of subretinal fluid or intraretinal fluid despite three consecutive  (monthly or bimonthly) aflibercept injection
Presence of active polyp on indocyanine green angiography</description>
    <arm_group_label>polypoidal choroidal vasculopathy without polyp</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  polypoidal choroidal vasculopathy without active polyp

          -  decreased visual acuity by subretinal fluid and hemorrhage involving foveal center

        Exclusion Criteria:

          -  polypoidal choroidal vasculopathy with active polyp

          -  previous photodynamic therapy more than three times

          -  anti-VEGF injection within one month

          -  photodynamic therapy or intraocular steroid treatment within three months
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Se Woong Kang, MD</last_name>
    <phone>82-2-3410-3548</phone>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ga Eun Cho, MD</last_name>
    <phone>82-10-2502-2436</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Seoul National University Bundang Hospital</name>
      <address>
        <city>Seongnam</city>
        <state>Gyunggi-do</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kyu Hyung Park, M.D.</last_name>
      <phone>82-32-787-7373</phone>
    </contact>
    <investigator>
      <last_name>Kyu Hyung Park, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Se Woong Kang, MD</last_name>
      <phone>02-3410-3548</phone>
    </contact>
    <investigator>
      <last_name>Se Woong Kang, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Konyang University Kim's Eye Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Tae Gon Lee, M.D.</last_name>
      <phone>82-2-3410-3548</phone>
    </contact>
    <investigator>
      <last_name>Tae Gon Lee, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>February 24, 2014</lastchanged_date>
  <firstreceived_date>February 10, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Endothelial Growth Factors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
